Related Experiment Video
Updated: Oct 31, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
History of Myasthenia Gravis Revisited
1İstanbul University Faculty of Medicine Retired Faculty Member, İstanbul, Turkey.
Abstract:
The first description of myasthenia gravis (MG) was given by Thomas Willis in 1672. MG was the focus of attention after mid-nineteenth century and a great amount of information has been accumulated in a span of 150 years. The aim of this review is to convey this information according to a particular systematic and to briefly relate the experience of Istanbul University. MG history was examined in four periods: 1868-1930, 1930-1960, 1960-1990, and 1990-2020. In the first period (1868-1930), all the clinical characteristics of MG were defined. Physiological/pharmacological studies on the transmission at the neuromuscular junction were initiated, and the concept of repetitive nerve stimulation emerged. A toxic agent was believed to be the cause of MG which appeared to resemble curare intoxication. Association of MG with thymus was noticed. No noteworthy progress was made in its treatment. In the second period (1930-1960), acetylcholine was discovered to be the transmitter at the neuromuscular junction. Repetitive nerve stimulation was used as a diagnostic test. The autoimmune nature of MG was suspected and experiments to this end started to give results. The hallmark of this period was the use of anticholinesterases and thymectomy in the treatment of MG. The third period (1960-1990) can probably be considered a revolutionary era for MG. Important immunological mechanisms (acetylcholine receptor isolation, discovery of anti-acetylcholine receptor antibodies) were clarified and the autoimmune nature of MG was demonstrated. Treatment modalities which completely changed the prognosis of MG, including positive pressure mechanic ventilation and corticosteroids as well as plasma exchange/IVIg and azathioprine, were put to use. In the fourth period (1990-2020), more immunological progress, including the discovery of anti-MuSK antibodies, was achieved. Videothoracoscopic thymectomy reduced the morbidity and mortality rate associated with surgery. New drugs emerged and clinical trials were performed. Valuable guidelines were published. In the last part of the review, the experience in MG of Istanbul University, a pioneer in Turkey, is related.
Insights
This review traces the 150-year history of myasthenia gravis (MG) research, highlighting key discoveries in its pathophysiology and treatment. It details advancements from early clinical descriptions to modern immunotherapies and surgical interventions for MG.
Area of Science:
- Neurology
- Immunology
- Medical History
Background:
- Myasthenia gravis (MG) has a documented history dating back to 1672.
- Significant advancements in understanding and treating MG have occurred over the last 150 years.
- This review systematically examines the historical progression of MG research and clinical practice.
Purpose of the Study:
- To provide a systematic review of the historical evolution of myasthenia gravis research.
- To chronicle the key scientific and clinical milestones in understanding MG.
- To present the experience of Istanbul University in managing myasthenia gravis.
Main Methods:
- Historical analysis of myasthenia gravis literature and clinical practice.
- Categorization of MG history into four distinct periods (1868-1930, 1930-1960, 1960-1990, 1990-2020).
- Review of diagnostic and therapeutic advancements throughout these periods.
Main Results:
- The first period (1868-1930) defined MG's clinical features and initiated studies on neuromuscular transmission.
- The second period (1930-1960) identified acetylcholine as the neurotransmitter and introduced anticholinesterases and thymectomy.
- The third period (1960-1990) revolutionized MG treatment with immunosuppressants and mechanical ventilation, clarifying its autoimmune basis.
- The fourth period (1990-2020) saw discoveries like anti-MuSK antibodies, minimally invasive surgery, and new therapeutic agents.
Conclusions:
- Myasthenia gravis research has progressed significantly, transforming from basic clinical observation to complex immunological understanding and targeted therapies.
- The development of diagnostic tools, understanding of autoimmune mechanisms, and introduction of novel treatments have dramatically improved MG patient outcomes.
- Istanbul University has played a pioneering role in advancing MG care in Turkey.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Muscle Contraction

